4th Quarter - Report
AVENUE SOLUTIONS for JAZZ PHARMACEUTICALS, INC.
Firm
Client
Income
$80,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug safety, prescription drug abuse, drug pricing; Inflation Reduction Act of 2022 (PL 117-169); S. 4348, FDA Safety and Landmark Advancements Act; H.R. 7667, Food and Drug Amendments of 2022 H.R. 2617, Consolidated Appropriations Act, 2023
| Lobbyist | Covered position, as disclosed |
|---|---|
| TRACY SPICER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.